Metabolome Profiling of Malignant Ascites Identifies Candidate Metabolic Biomarkers of Hepatocellular Carcinoma
- Авторы: Wang W.1, Wu Y.1, Zhang Q.2, Cui P.1
-
Учреждения:
- Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University
- Department of Hepatobiliary Spleen and Gastroenterology,, Henan Provincial Hospital of Traditional Chinese Medicine, Henan University of Chinese Medicine
- Выпуск: Том 31, № 13 (2024)
- Страницы: 1769-1780
- Раздел: Anti-Infectives and Infectious Diseases
- URL: https://medjrf.com/0929-8673/article/view/644326
- DOI: https://doi.org/10.2174/0929867330666230324153552
- ID: 644326
Цитировать
Полный текст
Аннотация
Background:Malignant ascites is one of the severe complications of hepatocellular carcinoma, which can be regarded as a unique tumor microenvironment of hepatocellular carcinoma. The identification of novel biomarkers in malignant ascites could be crucial to differentiate patients with hepatocellular carcinoma and cirrhotic ascites.
Objective:The study aimed to distinguish the metabolomics of malignant ascites in patients with hepatocellular carcinoma from that of non-malignant ascites (cirrhotic ascites).
Methods:Liquid chromatography-mass spectrometry was performed to analyze the differentially distributed biomarkers in patients with malignant ascites and hepatocellular carcinoma (n = 39), as well as in patients with cirrhotic ascites, which were taken as controls (n = 36).
Results:Our results suggest that the key factors associated with pathways, such as arachidonic acid, phenylalanine, and glutamic acid pathways, are potential ascitic fluidbased biomarkers for differentiating hepatocellular carcinoma with cirrhosis ascites; the results also provide a clinical pathophysiological interpretation of biomarkers and metabolic pathways relevant to disease status.
Conclusion:Our results suggest that the key factors associated with pathways, such as arachidonic acid, phenylalanine, and glutamic acid pathways, are potential ascitic fluidbased biomarkers for differentiating hepatocellular carcinoma with cirrhosis ascites; the results also provide a clinical pathophysiological interpretation of biomarkers and metabolic pathways relevant to disease status.
Ключевые слова
Об авторах
Weijia Wang
Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University
Email: info@benthamscience.net
Yue Wu
Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University
Email: info@benthamscience.net
Qinsheng Zhang
Department of Hepatobiliary Spleen and Gastroenterology,, Henan Provincial Hospital of Traditional Chinese Medicine, Henan University of Chinese Medicine
Автор, ответственный за переписку.
Email: info@benthamscience.net
Peilin Cui
Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University
Автор, ответственный за переписку.
Email: info@benthamscience.net
Список литературы
- Zheng, L.; Xu, M.; Xu, J.; Wu, K.; Fang, Q.; Liang, Y.; Zhou, S.; Cen, D.; Ji, L.; Han, W.; Cai, X. ELF3 promotes epithelialmesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell Death Dis., 2018, 9(3), 387. doi: 10.1038/s41419-018-0399-y PMID: 29523781
- El-Serag, H.B. Hepatocellular carcinoma. N. Engl. J. Med., 2011, 365(12), 1118-1127. doi: 10.1056/NEJMra1001683 PMID: 21992124
- Pavlova, N.N.; Thompson, C.B. The emerging hallmarks of cancer metabolism. Cell Metab., 2016, 23(1), 27-47. doi: 10.1016/j.cmet.2015.12.006 PMID: 26771115
- Cavazzoni, E.; Bugiantella, W.; Graziosi, L.; Franceschini, M.S.; Donini, A. Malignant ascites: Pathophysiology and treatment. Int. J. Clin. Oncol., 2013, 18(1), 1-9. doi: 10.1007/s10147-012-0396-6 PMID: 22460778
- Watala, C.; Karolczak, K.; Kassassir, H.; Talar, M.; Przygodzki, T.; Maczynska, K.; Labieniec-Watala, M. How do the full-generation poly(amido)amine (PAMAM) dendrimers activate blood platelets? Activation of circulating platelets and formation of "fibrinogen aggregates" in the presence of polycations. Int. J. Pharm., 2016, 503(1-2), 247-261. doi: 10.1016/j.ijpharm.2015.08.073 PMID: 26319628
- Pillai, R.C.; Fraser, J.F.; Ziegenfuss, M.; Bhaskar, B. Influence of circulating levels of fibrinogen and perioperative coagulation parameters on predicting postoperative blood loss in cardiac surgery: A prospective observational study. J. Card. Surg., 2014, 29(2), 189-195. doi: 10.1111/jocs.12255 PMID: 24734282
- Moore, C.M.; Van Thiel, D.H. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J. Hepatol., 2013, 5(5), 251-263. doi: 10.4254/wjh.v5.i5.251 PMID: 23717736
- Oberg, A.L.; Mahoney, D.W. Statistical methods for quantitative mass spectrometry proteomic experiments with labeling. BMC Bioinformatics, 2012, 13(S16), 7. doi: 10.1186/1471-2105-13-S16-S7
- Thompson, J.W.; Forrester, M.T.; Moseley, M.A.; Foster, M.W. Solid-phase capture for the detection and relative quantification of S-nitrosoproteins by mass spectrometry. Methods, 2013, 62(2), 130-137. doi: 10.1016/j.ymeth.2012.10.001 PMID: 23064468
- Mehrotra, S.; Goyal, V. Evaluation of designer crops for biosafety-A scientists perspective. Gene, 2013, 515(2), 241-248. doi: 10.1016/j.gene.2012.12.029 PMID: 23266812
- Sauzay, C.; Petit, A.; Bourgeois, A.M.; Barbare, J.C.; Chauffert, B.; Galmiche, A.; Houessinon, A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta, 2016, 463, 39-44.
- Lindon, J.C.; Holmes, E.; Nicholson, J.K. Metabonomics in pharmaceutical R & D. FEBS J., 2007, 274(5), 1140-1151. doi: 10.1111/j.1742-4658.2007.05673.x PMID: 17298438
- Zhang, J.; Liang, R.; Wei, J.; Ye, J.; He, Q.; ChunlingYuan; Ye, J.; Li, Y.; Liu, Z.; Lin, Y. Identification of candidate biomarkers in malignant ascites from patients with hepatocellular carcinoma by iTRAQ-based quantitative proteomic analysis. BioMed Res. Int., 2018, 2018, 1-11. doi: 10.1155/2018/5484976 PMID: 30345303
- Lee, S.S.; Min, H.J.; Choi, J.Y.; Cho, H.C.; Kim, J.J.; Lee, J.M.; Kim, H.J.; Ha, C.Y.; Kim, H.J.; Kim, T.H.; Kim, J.H.; Lee, O.J. Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis. BMC Gastroenterol., 2016, 16(1), 132. doi: 10.1186/s12876-016-0546-9 PMID: 27733127
- Sui, Z.; Li, Q.; Zhu, L.; Wang, Z.; Lv, C.; Liu, R.; Xu, H.; He, B.; Li, Z.; Bi, K. An integrative investigation of the toxicity of Aconiti kusnezoffii radix and the attenuation effect of its processed drug using a UHPLC-Q-TOF based rat serum and urine metabolomics strategy. J. Pharm. Biomed. Anal., 2017, 145, 240-247. doi: 10.1016/j.jpba.2017.06.049 PMID: 28668652
- Wang, X.; Zhang, A.; Sun, H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology, 2013, 57(5), 2072-2077. doi: 10.1002/hep.26130 PMID: 23150189
- Jiang, M.; Lu, C.; Zhang, C.; Yang, J.; Tan, Y.; Lu, A.; Chan, K. Syndrome differentiation in modern research of traditional Chinese medicine. J. Ethnopharmacol., 2012, 140(3), 634-642. doi: 10.1016/j.jep.2012.01.033 PMID: 22322251
- Zira, A.N.; Theocharis, S.E.; Mitropoulos, D.; Migdalis, V.; Mikros, E. (1)H NMR metabonomic analysis in renal cell carcinoma: A possible diagnostic tool. J. Proteome Res., 2010, 9(8), 4038-4044. doi: 10.1021/pr100226m PMID: 20527959
- Lu, X.; Zhao, X.; Bai, C.; Zhao, C.; Lu, G.; Xu, G. LCMS-based metabonomics analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 866(1-2), 64-76. doi: 10.1016/j.jchromb.2007.10.022 PMID: 17983864
- Jiang, W.; Qiu, Y.; Ni, Y.; Su, M.; Jia, W.; Du, X. An automated data analysis pipeline for GC-TOF-MS metabonomics studies. J. Proteome Res., 2010, 9(11), 5974-5981. doi: 10.1021/pr1007703 PMID: 20825247
- Safaei, A.; Arefi Oskouie, A.; Mohebbi, S.R.; Rezaei-Tavirani, M.; Mahboubi, M.; Peyvandi, M.; Okhovatian, F.; Zamanian-Azodi, M. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol. Hepatol. Bed Bench, 2016, 9(3), 158-173. PMID: 27458508
- Cui, W.; Zhang, J.; Wu, D.; Zhang, J.; Zhou, H.; Rong, Y.; Liu, F.; Wei, B.; Xu, X. Ponicidin suppresses pancreatic cancer growth by inducing ferroptosis: Insight gained by mass spectrometry-based metabolomics. Phytomedicine, 2022, 98, 153943. doi: 10.1016/j.phymed.2022.153943 PMID: 35104766
- Zhang, H.; Bian, S.; Xu, Z.; Gao, M.; Wang, H.; Zhang, J.; Zhang, M.; Ke, Y.; Wang, W.; Chen, Z.S.; Xu, H. The effect and mechanistic study of encequidar on reversing the resistance of SW620/AD300 cells to doxorubicin. Biochem. Pharmacol., 2022, 205, 115258. doi: 10.1016/j.bcp.2022.115258 PMID: 36179932
- Jha, V.K.; Shenoy, G.; Borpujari, P.J.; Banerjee, M. Biomarkers of malignant ascites-a myth or reality. Med. J. Armed Forces India, 2011, 67(4), 398. doi: 10.1016/S0377-1237(11)60100-7 PMID: 27365864
- Coloff, J.L.; Murphy, J.P.; Braun, C.R.; Harris, I.S.; Shelton, L.M.; Kami, K.; Gygi, S.P.; Selfors, L.M.; Brugge, J.S. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab., 2016, 23(5), 867-880. doi: 10.1016/j.cmet.2016.03.016 PMID: 27133130
- Prickett, T.D.; Samuels, Y. Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer. Clin. Cancer Res., 2012, 18(16), 4240-4246. doi: 10.1158/1078-0432.CCR-11-1217 PMID: 22648273
- Matsuda, K. Novel susceptibility loci for hepatocellular carcinoma in chronic HBV carriers. Hepatobiliary Surg. Nutr., 2012, 1(1), 59-60. PMID: 24570905
- Nahon, P.; Amathieu, R.; Triba, M.N.; Bouchemal, N.; Nault, J.C.; Ziol, M.; Seror, O.; Dhonneur, G.; Trinchet, J.C.; Beaugrand, M.; Le Moyec, L. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin. Cancer Res., 2012, 18(24), 6714-6722. doi: 10.1158/1078-0432.CCR-12-1099 PMID: 23136190
- Han, M.; Xie, M.; Han, J.; Yuan, D.; Yang, T.; Xie, Y. Development and validation of a rapid, selective, and sensitive LCMS/MS method for simultaneous determination of d- and l-amino acids in human serum: application to the study of hepatocellular carcinoma. Anal. Bioanal. Chem., 2018, 410(10), 2517-2531. doi: 10.1007/s00216-018-0883-3 PMID: 29492623
- Keshet, R.; Szlosarek, P.; Carracedo, A.; Erez, A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat. Rev. Cancer, 2018, 18(10), 634-645. doi: 10.1038/s41568-018-0054-z PMID: 30194362
- Kim, D.; Cho, E.; Yu, K.S.; Jang, I.J.; Yoon, J.H.; Park, T.; Cho, J.Y. Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers, 2019, 11(10), 1497. doi: 10.3390/cancers11101497 PMID: 31590436
- Spinelli, J.B.; Yoon, H.; Ringel, A.E.; Jeanfavre, S.; Clish, C.B.; Haigis, M.C. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science, 2017, 358(6365), 941-946. doi: 10.1126/science.aam9305 PMID: 29025995
- Brosnan, M.E.; Brosnan, J.T. Hepatic glutamate metabolism: A tale of 2 hepatocytes. Am. J. Clin. Nutr., 2009, 90(3), 857S-861S. doi: 10.3945/ajcn.2009.27462Z PMID: 19625684
- Mian, A.; Lee, B. Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism. Trends Mol. Med., 2002, 8(12), 583-589. doi: 10.1016/S1471-4914(02)02437-1 PMID: 12470992
- Gong, Z.G.; Zhao, W.; Zhang, J.; Wu, X.; Hu, J.; Yin, G.C.; Xu, Y.J. Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget, 2017, 8(38), 63890-63900. doi: 10.18632/oncotarget.19173 PMID: 28969038
- Yang, F.; Li, J.; Deng, H.; Wang, Y.; Lei, C.; Wang, Q.; Xiang, J.; Liang, L.; Xia, J.; Pan, X.; Li, X.; Long, Q.; Chang, L.; Xu, P.; Huang, A.; Wang, K.; Tang, N. GSTZ 1-1 deficiency activates NRF 2/ IGF 1R Axis in HCC via accumulation of oncometabolite succinylacetone. EMBO J., 2019, 38(15), e101964. doi: 10.15252/embj.2019101964 PMID: 31267557
- Linkous, A.G.; Yazlovitskaya, E.M.; Hallahan, D.E. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J. Natl. Cancer Inst., 2010, 102(18), 1398-1412. doi: 10.1093/jnci/djq290 PMID: 20729478
- Jee, S.H.; Kim, M.; Kim, M.; Yoo, H.J.; Kim, H.; Jung, K.J.; Hong, S.; Lee, J.H. Metabolomics profiles of hepatocellular carcinoma in a Korean prospective cohort: The Korean cancer prevention study-II. Cancer Prev. Res. (Phila.), 2018, 11(5), 303-312. doi: 10.1158/1940-6207.CAPR-17-0249 PMID: 29500188
- Sun, X.M.; Dong, W.G.; Yu, B.P.; Luo, H.S.; Yu, J.P. Detection of type IV collagenase activity in malignant ascites. World J. Gastroenterol., 2003, 9(11), 2592-2595. doi: 10.3748/wjg.v9.i11.2592 PMID: 14606104
- Kountouras, J.; Boura, P.; Tsapas, G.; Charisis, K.; Magoula, I.; Tsakiri, I. Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites. Anticancer Res., 1993, 13(6B), 2441-2445. PMID: 8135481
- Wang, X.; Lin, G.; Huang, Y. Study on biomarkers of serum and ascites in patients with liver cirrhosis or liver cancer. World Chin. Digestion J., 1999, 7, 642-643.
- Xu, P.; Zhu, B. Clinical significance of serum and ascites α-L-fucosylase in liver cancer. Jiangsu Med., 1990, 16(2), 91-92.
Дополнительные файлы
